-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

622.O2.6 622. Lymphomas: Translational – Non-Genetic: Demystifying the Complexity of the Lymphoma Tumor Microenvironment and Immune Responses

Symposia: Lymphomas: Translational – Non-Genetic Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Combination therapy, Adult, Fundamental Science, Translational Research, Lymphomas, Non-Hodgkin lymphoma, Clinical Practice (Health Services and Quality), Drug development, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Indolent lymphoma, Immune mechanism, Aggressive lymphoma, Treatment Considerations, Biological therapies, Immunology, Lymphoid Malignancies, Computational biology, Biological Processes, Microbiome, Technology and Procedures, Human, Study Population, Imaging, Measurable Residual Disease , Molecular testing, Omics technologies, Serologic Tests
Sunday, December 8, 2024: 4:30 PM-6:00 PM
Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)
Moderators:
Santosha A. Vardhana, MD, PhD, and Benoit Tessoulin, CHU Nantes
Disclosures:
No relevant conflicts of interest to declare.
This session will describe the lymphoma TME and how new therapies interact with this complex immune: tumour interface.
4:30 PM

Xubin Li, PhD1*, Kartik Singhal2*, Qing Deng, PhD3*, Dai Chihara, MD, PhD4, David A Russler-Germain, MD, PhD5, Usama Hussein1*, Jennifer Ann Foltz, PhD6*, Jared Henderson, PhD7*, Ashley Wilson7*, Evelyn Schmidt8*, Imran A. Nizamuddin, MD9, Tommy Dinh1*, Ryan Sun10*, Akhil Kesaraju, BA11*, Laura K. Hilton, PhD12*, David W. Scott, MBChB, PhD13, Francisco Vega, MD, PhD14, Christopher R. Flowers, MD, MS4, Obi Griffith, PhD6*, Todd A Fehniger15, Malachi Griffith, PhD6* and Michael R. Green, PhD16

1University of Texas MD Anderson Cancer Center, Houston, TX
2Washington University St. Louis, St Louis, MO
3Department of Lymphoma & Myeloma, The University of Texas at MD Anderson Cancer, Houston, TX
4Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
5Siteman Cancer Center, Division of Oncology, Washington University School of Medicine, Saint Louis, MO
6Washington University School of Medicine in St. Louis, St Louis, MO
7The University of Texas MD Anderson Cancer Center, Houston, TX
8Washington University St. Louis, St. Louis
9Division of Oncology, Washington University School of Medicine, St. Louis, MO
10Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
11Washington University School of Medicine in St. Louis, Saint Louis, MO
12Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada
13Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada
14MD Anderson Cancer Center , Houston, TX
15Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO
16Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Friendswood, TX

4:45 PM

Koorosh Korfi, PhD1, Sabine Wilson, PhD2*, Zhiwen Jiang, PhD3*, Ailsa Christiansen, PhD4*, Sreenath Krishnan3*, Candice Jamois, PharmD3*, Annika Blank, PhD5*, Alexandra Epp6*, Abraham Silva6*, Philip Knuckles3*, Joanne Hayward4*, Johannes Sam, PhD5*, Katharina Lechner7*, Natalie Dimier, PhD8*, Paolo F. Caimi9, Lorenzo Falchi, MD10, Giuseppe Gritti, MD, PhD11*, Franck Morschhauser, MD, PhD12, Martin Hutchings, MD, PhD13, Michael J. Dickinson, MBBS, DMedSci14 and Carmelo Carlo-Stella, MD15

1Pharma Research and Early Development, Innovation Center Zürich, Roche, Zürich, Switzerland
2Pharma Research and Early Development, Roche Innovation Center Welwyn, Roche, Welwyn, United Kingdom
3Pharma Research and Early Development, Roche Innovation Center Basel, Roche, Basel, Switzerland
4A4P Consulting Ltd, Sandwich, United Kingdom
5Pharma Research and Early Development, Roche Innovation Center Zurich, Roche, Schlieren, Switzerland
6Pharma Research and Early Development, Roche Innovation Center Munich, Roche, Penzberg, Germany
7Pharma Research and Early Development, Innovation Center Munich, Roche, Munich, Germany
8Pharma Research and Early Development, Innovation Center Welwyn, Roche, Welwyn, United Kingdom
9Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
10Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
11Hematology and BMT Unit, ASST Ospedale Papa Giovanni XXIII, Bergamo, Italy
12Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France
13Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
14Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
15Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy

5:00 PM

Nicholas J. Haradhvala, PhD1*, Stephanie Yiu, PhD2,3*, Sam Sadigh, MD4,5*, Laura Beckmann, MD6,7*, Amber Pospistle1*, Stephanie Deng6*, Santiago Rivero6*, Yao Yu Yeo2,8*, Katie Maurer, MD, PhD1,5,6, Vignesh Shanmugam, MD1,4,5, McKayla Van Orden9*, Wesley S Lu, BS9*, Shuqiang Li, PhD1,9*, Kenneth J. Livak, PhD9*, Huaying Qiu10*, Yuzhou Chang10,11*, Ankit Basak1,12,13*, Alex K Shalek, PhD1,13,14*, Mikaela M. McDonough15*, Robert A. Redd, MS16*, Scott J. Rodig, MD, PhD4,5,17, Satyen Gohil, MD PhD18*, Donna S. Neuberg, ScD16, Catherine J. Wu, MD1,5,6*, Gad Getz, PhD1,5,19,20*, Sizun Jiang, PhD1,2,5,21 and Erin M. Parry, MD, PhD1,5,6

1Broad Institute of MIT and Harvard, Cambridge, MA
2Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA
3Wyss Institute at Harvard, Boston, MA
4Department of Pathology, Brigham and Women's Hospital, Boston, MA
5Harvard Medical School, Boston, MA
6Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
7Faculty of Medicine and Cologne University Hospital, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany, Cologne, Germany
8Program in Virology, Harvard Medical School, Boston
9Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA
10Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston
11The Ohio State University, Columbus
12Institute for Medical Engineering & Science and Department of Chemistry, Massachusetts Institute of Technology, Cambridge
13Ragon Institute of Mass General, MIT and Harvard, Boston, MA
14Institute for Medical Engineering & Science and Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA
15Dana-Farber Cancer Institute, Boston, MA
16Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
17Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA
18University College London Hospitals NHS Foundation Trust, London, United Kingdom
19Department of Pathology, Massachusetts General Hospital, Boston, MA
20Krantz Family Center for Cancer Research and Dept. of Pathology, Massachusetts General Hospital, Boston, MA
21Department of Pathology, Dana-Farber Cancer Institute, Boston, MA

5:15 PM

Yifan Yin1*, Tomohiro Aoki, MD, PhD2, Shinya Rai, MD, PhD1, Aixiang Jiang, MS1*, Alexander Xu, PhD3*, Luke O’Brien, BSc4*, Jan Delabie, MD, PhD5*, Lauren Camille Chong, MSc6*, Stacy Hung, PhD4*, Akil Merchant, MD3, David W. Scott, MBChB, PhD7, Kerry J. Savage, MD, MSc4 and Christian Steidl, MD, PhD1

1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada
2Princess Margaret Cancer Centre, Toronto, ON, Canada
3Division of Hematology and Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA
4BC Cancer, Vancouver, BC, Canada
5Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
6BC Cancer Agency, Vancouver, BC, CAN
7Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada

5:30 PM

Anu Korula, MD, DM, MRCP1*, Arun Arunachalam, MD2*, Uday Kulkarni, MD, DM3, Phaneendra Venkateswara Rao Datari, MD2*, Sumith Mathew, MD4*, Aswin Anand PAI, MSc5*, Sushil Selvarajan, MD, DM3*, Fouzia N., MD, DM2*, Aby Abraham, MD, DM3*, Biju George, MD, DM3, Poonkuzhali Balasubramanian, MSc, PhD2* and Vikram Mathews, MD, DM6

1Department of Haematology, Christian Medical College & Hospital, Vellore, India
2Department of Haematology, Christian Medical College, Vellore, India
3Department of Haematology, Christian Medical College Ranipet Campus, Ranipet, India
4Department of Clinical Pharmacology, Christian Medical College, Vellore, India
5Department of Haematology, Christian Medical College, VELLORE, TAMIL NADU, India
6Department of Haematology, Christian Medical College Vellore, Ranipet Campus, India

5:45 PM

Joseph G. Schroers-Martin, MD1, Andrea Garofalo, BS, BA2, Shuyu Shi3, Joanne Soo, MD4*, Helen Luikart, RN, MSN5*, Brian J. Sworder, MD, PhD6, Jan Boegeholz, MD7, Xiaoman Kang, BS8*, Mari Olsen, BS2*, Chih Long Liu, PhD2*, Feng Tian, PhD2*, Annette Skoda5*, Gerardo Gamino5*, Dave Jimil Morales5*, Kathrin Freystaetter, MD9*, Sean Agbor-Enoh, MD, PhD10*, Martin Andreas, MBA, PhD11*, Dan Chambers, MBBS MRCP FRACP MD12*, Maria Crespo-Leiro, MD, PhD13*, Gundeep Dhillon, MBBS14*, Maryjane Farr, MD15*, Seth Hollander, MD16*, Abdallah Kfoury, MD17*, Evan Kransdorf, MD, PhD18*, Marcel Nijland, MD, PhD19*, Jayant Raikhelkar, MD20*, David Rosenthal, MD21*, Heather Ross, MD22*, Stijn Verleden, PhD23*, Lorenzo Zaffiri, MD, PhD18*, Andreas Zuckermann, MD9*, David Kurtz, MD, PhD2,24, Yasodha Natkunam, MD, PhD25, Maximilian Diehn, MD, PhD26,27*, Kiran Khush, MD5* and Ash A. Alizadeh, MD, PhD28

1Department of Medicine, Division of Oncology and Hematology, Stanford University, Menlo Park, CA
2Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA
3Dept. of Bioengineering, Schools of Engineering and Medicine, Stanford, CA
4Stanford University, Stanford, CA
5Division of Cardiovascular Medicine, Stanford University, Stanford, CA
6Division of Hematology and Oncology, University of California, Irvine, Irvine, CA
7Divisions of Hematology and Oncology, Stanford University, Stanford, CA
8Department of Medicine, Division of Oncology, Stanford University, Stanford, CA
9Medical University of Vienna, Vienna, Austria
10National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
11University of Vienna, Vienna, Austria
12University of Queensland, Brisbane, Australia
13Universitario A Coruña, La Coruna, Spain
14Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University, Stanford, CA
15Heart Failure, Mechanical Circulatory Support and Transplant, UT Southwestern, Dallas, TX
16Stanford University, Palo Alto, CA
17Intermountain Heart Institute, Murray, UT
18Cedars Sinai Medical Center, Beverly Hills, CA
19University Medical Center Groningen and University of Groningen, Groningen, Netherlands
20Columbia University, New York, NY
21Department of Pediatrics, Division of Cardiology, Stanford University, Stanford, CA
22Toronto General Hospital, University Health Network, Toronto, Canada
23Katholieke Universiteit Leuven, Leuven, Belgium
24Department of Medicine (Oncology), Stanford University, Palo Alto, CA
25Department of Pathology, Stanford University School of Medicine, Stanford, CA
26Department of Radiation Oncology, Stanford University, Stanford, CA
27Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA
28Stanford University, San Mateo, CA

*signifies non-member of ASH